Clinical trials · New York
Metastatic Breast Cancer clinical trials in New York
We’re tracking 186 recruiting metastatic breast cancer studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Commack, New YorkAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Commack, New YorkAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Lake Success, New YorkAges 18–99 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mineola, New YorkAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Commack, New YorkAges 18 years+ - NCT05219695RecruitingPhase 1
Ultrasound imaging and treatment for breast tumors
This study uses focused ultrasound waves to create detailed images of breast tumors and deliver targeted treatment. It aims to improve how breast tumors are treated while minimizing damage to healthy tissue.
New York, New YorkAges 18 years+ - NCT04371913Recruiting
Second chance breast-conserving treatment for certain breast recurrences
This trial studies a personalized plan to remove and re-treat a limited breast recurrence while trying to keep the breast. It may help people whose cancer came back in the same breast after prior breast-conserving treatment, with certain size and spread limits.
New York, New YorkAges 19–90 - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Albany, New YorkAges 18–100 - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
The Bronx, New YorkAges 18 years+ - NCT07172282RecruitingEarly Phase 1
Immunotherapy for colorectal cancer liver metastases
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
Lake Success, New YorkAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
New York, New YorkAges 18 years+ - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
New York, New YorkAges 18 years+ - NCT06134375RecruitingPhase 1/Phase 2
TM plus capecitabine for triple-negative breast cancer
This trial tests a drug called tetrathiomolybdate (TM) combined with capecitabine for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy and surgery. The goal is to see if this combination can help prevent the cancer from coming back.
New York, New YorkAges 18–80 - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
New York, New YorkAges 18 years+ - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Long Island City, New YorkAges 18 years+
Metastatic Breast Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting metastatic breast cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Columbia University Irving Medical Center · 4 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Memorial Sloan Kettering Westchester · 2 studies
- New York Oncology Hematology · 2 studies
- NYU Langone Hospital - Long Island · 2 studies
What taking part in a metastatic breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Breast Cancer trials in other states
Common questions
- Are there metastatic breast cancer clinical trials in New York?
- Yes. We're currently tracking 186 recruiting metastatic breast cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic breast cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic breast cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.